Stocks To Buy Now

Blog

The Stocks To Buy Now Blog

Our team has been covering the micro- and small-cap markets for more than a decade, exploring a wide variety of trends, technology and news in every industry. The Stocks to Buy Now blog seeks out undervalued companies, covers their news, breaks down the jargon, and delivers accurate and timely information to you on a daily basis.

If you’re looking for market insight, undervalued gems, and an assortment of investment options, read on.

Fastfunds Financial Corp. (FFFC) Cannabis Sector Picks-and-Shovels Play Spans Financial Services, Security & Grow Op Antimicrobial Systems

As the ongoing “Green Rush” continues to pick up momentum across the U.S., with more and more states inexorably on the road to either passing transformative medical marijuana legislation that is effectively the narrow end of the wedge, or blanket decriminalization, as is the case in Alaska, Colorado ($700 million in 2014), Oregon, Washington, and […]

RestorGenex Corp. (RESX) Looks to Address Underserved Oncology Indications with Innovative Product Candidate

RestorGenex Corp. (OTCQX: RESX) is a specialty biopharmaceutical company focused on the development of a portfolio of first-in-class therapeutic products to treat diseases across the oncologic, ophthalmologic and dermatologic space. The company’s lead product candidate, RES-529, is a novel PI3K/Akt/mTOR pathway inhibitor that has completed two phase I clinical trials for the treatment of age-related […]

Cherubim Interests, Inc. (CHIT) Sharpens Focus on Advancing its Proprietary Cultivation Technology

Cherubim Interests is led by highly experienced directors and a notable management team proficient in specific disciplines of property management, construction and finance. The company has committed these specialties to sharpen the company’s focus on alternative construction and real estate development. Primarily concentrated on the real estate development and controlled environment agriculture sectors, Cherubim Interests […]

Avant Diagnostics, Inc. (AVDX) Seeking FDA Clearance for Innovative Diagnostic Tool

Avant Diagnostics, Inc. (OTC: AVDX) is a medical diagnostic technology company specializing in large panel biomarker screening. The company’s first test, OvaDx®, is being developed in conjunction with Arrayit Corporation (OTCQB: ARYC) as the market’s first large panel biomarker screening test for pre-symptomatic ovarian cancer. In preclinical research studies, OvaDx demonstrated high sensitivity and specificity […]

Hemp, Inc. (HEMPD) Announces Launch of National Media Campaign, Approaches Completion of Decortication Plant

In an effort to elevate its cosmeceutical and nutraceutical product lines, Hemp, Inc. recently announced a full media partnership and public relations agreement with Freedom Leaf, Inc. (OTC: FRLF), a leading marijuana-related news, multimedia, entertainment, public relations and branding firm. Under the terms of this six-month campaign, Hemp, Inc. will receive a full-page advertisement in […]

International Stem Cell Corporation (ISCOD) Leading the Way in Emerging Field of Regenerative Medicine with Parthenogenetic Stem Cell Technology

International Stem Cell Corporation is a biotechnology company utilizing a proprietary new stem cell technology known as parthenogenesis to significantly advance the field of regenerative medicine. The company’s innovative technology uses unfertilized human eggs to create human pluripotent stem cells (hpSC) that can be immune-matched to millions of people around the globe. These stem cells […]

On the Move Systems (OMVS) Sees Opportunity to Fuel Additional Trucking Industry Growth

On the Move Systems’ (OMVS) upcoming “Uber-for-Trucking” on-demand platform is expected to do well, especially since the nation’s trucking industry is currently in the midst of an impressive growth spurt. The company’s platform will offer freight haulers a cutting-edge technology based solution to encourage continued growth. The American Trucking Associations (ATA) recently published its U.S. […]

 

From Our Blog

LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) Has the World’s Only Clinical-Stage PP2A Inhibitor, Poised to Improve Cancer Treatment Outcomes

March 31, 2026

LIXTE Biotechnology Holdings (NASDAQ: LIXT), a clinical-stage pharmaceutical company, is in the unique position of holding the world’s only clinical-stage protein phosphatase 2A (“PP2A”) inhibitor, called LB-100. The LB-100 compound is a proprietary small-molecule PP2A inhibitor that is designed to target protein phosphatase 2A (“PP2A”), introducing a potential new treatment paradigm aimed at enhancing existing […]

Rotate your device 90° to view site.